Search research articles
Contact Us
Filters
Showing results (171-180 of 205) with videos related to
Page
of 21
Sort By:
The Oncologist
|
July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapy
Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Jarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
Ann W Silk, Christopher A Barker, Shailender Bhatia, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
Yujie Zhao, Jarushka Naidoo, Michael Conroy, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Alvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Cancer Immunology Research
|
March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
Mari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
Maria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo, Karisa C Schreck, Wei Fu, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 205) with videos related to
Sort By:
Page
of 21
The Oncologist
|
July 27, 2024
Immune-related encephalitis after immune checkpoint inhibitor therapy
Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Jarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
Paolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
Ann W Silk, Christopher A Barker, Shailender Bhatia, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability
Yujie Zhao, Jarushka Naidoo, Michael Conroy, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 16, 2020
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Alvin P Makohon-Moore, Evan J Lipson, Jody E Hooper, et al.
Cancer Immunology Research
|
March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
Mari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
Maria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer
|
August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo, Karisa C Schreck, Wei Fu, et al.
Page
of 21